UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 23, 2020

 

 

BioLargo, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware

 

000-19709

 

65-0159115

(State or other jurisdiction

of incorporation)

 

(Commission File Number)

 

(IRS Employer

Identification No.)

 

 

14921 Chestnut St., Westminster, California

 

92683

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (888) 400-2863

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock

BLGO

OTCQB

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company.          ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.                    ☐

 

 

 

Item 5.07      Submission of Matters to a Vote of Security Holders

 

The Company held its 2020 annual stockholder meeting on July 23, 2020. The following matters were each submitted to a vote of stockholders through the solicitation of proxies or otherwise:

 

 

1.

A proposal to elect the following seven individuals to our Board of Directors: Dennis P. Calvert, Kenneth R. Code, Dennis E. Marshall, Joseph L. Provenzano, Kent C. Roberts II, John S. Runyan and Jack B. Strommen.

 

 

2.

Advisory approval of the Company’s executive compensation.

 

 

3.

A proposal to ratify the appointment of Haskell & White LLP as our independent registered public accounting firm for the 2020 fiscal year. 

 

 

4.

A proposal to re-authorize a reverse stock split of our common stock at a ratio between one-for-four (1:4) and one-for-twenty (1:20), if and as determined by our board of directors, at any time before the next meeting of stockholders of the Company.  

 

 

5.

A proposal to authorize a reduction of the number of shares of common stock authorized by our Amended and Restated Certificate of Incorporation, if and in an amount as determined by our board of directors.

 

A quorum was present in person or by proxy. Each matter was approved. The voting results are as follows:

 

Proposal One

 

Votes For

   

Votes

Withheld

   

Broker

Non-Vote

   

Total Votes (For +

Withheld)

         

Dennis P. Calvert

    74,258,518       2,239,515       47,528,072       76,498,033          

Kenneth R. Code

    74,382,858       2,115,175       47,528,072       76,498,033          

Dennis E. Marshall

    73,591,322       2,906,711       47,528,072       76,498,033          

Joseph L. Provenzano

    73,594,302       2,903,731       47,528,072       76,498,033          

Kent C. Roberts II

    73,618,727       2,879,306       47,528,072       76,498,033          

John S. Runyan

    73,620,966       2,877,067       47,528,072       76,498,033          

Jack B. Strommen

    74,289,295       2,208,738       47,528,072       76,498,033          

 

Proposals 2 - 5

   

Votes For

   

Votes

Against

   

Votes Abstain

   

Broker Non-Vote

   

Total votes

 
2       72,180,828       2,950,599       1,752,675       47,142,003       76,884,102  
3       122,714,446       171,136       752,453       388,070       123,638,035  
4       106,078,764       16,696,049       1,251,288       -       124,026,101  
5       111,661,752       10,943,152       1,033,130       388,071       123,638,034  

 

There were no director nominees other than as set forth above. For the Advisory Approval of Executive Compensation, prior year votes are as follows:

 

Year

 

Votes For

   

Votes Against

   

Votes Abstain

   

Broker Non-

Vote

 

2017

    27,248,643       343,971       242,499       28,177,525  

2018

    34,117,919       1,102,804       247,388       35,954,467  

2019

    41,886,128       1,486,549       7,956,269       44,918,490  

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: July 28, 2020

 

 

 

BIOLARGO, INC.

 
           
 

 

 

 

 

 

By:

/s/ Dennis P. Calvert

 
 

 

 

 

 

 

 

Dennis P. Calvert

 
 

 

 

 

 

 

 

President and Chief Executive Officer

 

 

 
BioLargo (QB) (USOTC:BLGO)
Historical Stock Chart
From Oct 2020 to Nov 2020 Click Here for more BioLargo (QB) Charts.
BioLargo (QB) (USOTC:BLGO)
Historical Stock Chart
From Nov 2019 to Nov 2020 Click Here for more BioLargo (QB) Charts.